ライフサイエンスコーパス: developing country

1 te and agricultural income to self-harm in a developing country.

2 y of monovalent rotavirus vaccine (RV1) in a developing country.

3 ed in national immunization programs in many developing countries.

4 cine to control canine-transmitted rabies in developing countries.

5 ies within entrepreneurial ecosystems in six developing countries.

6 challenges to more effective vaccination in developing countries.

7 hain, or cold chain, is rapidly expanding in developing countries.

8 rointestinal illness among young children in developing countries.

9 birth cohort due to growth faltering in 137 developing countries.

10 partners, including vaccine manufacturers in developing countries.

11 ical service as a public health commodity in developing countries.

12 ied the economic cost of growth faltering in developing countries.

13 e elderly or for patients with endemic BL in developing countries.

14 by the lack of accurate data, especially in developing countries.

15 ral rotavirus vaccines are less effective in developing countries.

16 d world, it presents a significant burden in developing countries.

17 lic health priority worldwide, especially in developing countries.

18 are the leading risk factors for stunting in developing countries.

19 hat can enable more effective vaccination in developing countries.

20 n developed countries, but are increasing in developing countries.

21 can expand influenza vaccination coverage in developing countries.

22 sform efforts to track and target poverty in developing countries.

23 s from 24 countries, of which 21 represented developing countries.

24 t are attributable to 18 risk factors in 137 developing countries.

25 d disease surveillance in both developed and developing countries.

26 iagnosis of DENV in clinics and hospitals in developing countries.

27 se, but this has been little investigated in developing countries.

28 ess to drinking water for millions living in developing countries.

29 approximately 3% of individuals traveling to developing countries.

30 der the age of 5 years in both developed and developing countries.

31 l but preventable cause of mortality in many developing countries.

32 hildren under the age of 2 years who live in developing countries.

33 cer health disparities between developed and developing countries.

34 on RSV has yielded substantial new data from developing countries.

35 thods used for electronic waste treatment in developing countries.

36 an underrecognized cause of illness in many developing countries.

37 s limiting their applicability especially in developing countries.

38 tries and the emerging cause of blindness in developing countries.

39 ks, and clinical trials of co-trimoxazole in developing countries.

40 n and a leading cause of infant mortality in developing countries.

41 water are major contributors to diarrhea in developing countries.

42 tension treatment and control, especially in developing countries.

43 phi remains a major public health problem in developing countries.

44 y strong trend of vulnerability reduction in developing countries.

45 However, IPV is unaffordable for many developing countries.

46 ealth challenge in Bangladesh and some other developing countries.

47 ing and low cost breathable architecture for developing countries.

48 e been largely unavailable to most people in developing countries.

49 blood groups, which is promising for use in developing countries.

50 nder-privileged communities in developed and developing countries.

51 ving accessibility to medical diagnostics in developing countries.

52 causes of visual impairment and blindness in developing countries.

53 en provided to maintain or improve health in developing countries.

54 and economic losses as well as mortality in developing countries.

55 ays to offer viable alternatives to coal for developing countries.

56 of premium importance for the agriculture of developing countries.

57 um antimicrobial drug that is widely used in developing countries.

58 ion to action for the agricultural sector in developing countries.

59 use of severe dehydrating gastroenteritis in developing countries.

60 and provision of treatment, particularly in developing countries.

61 4 leading diarrheal pathogens in children in developing countries.

62 ter-life cognition and schooling outcomes in developing countries.

63 fe saved through intervention was US$4498 in developing countries.

64 alent oral poliovirus vaccine (tOPV) in some developing countries.

65 stating maternal complication of delivery in developing countries.

66 able for all children, particularly those in developing countries.

67 defect recurrence; and studies conducted in developing countries.

68 nd are a leading cause of infant diarrhea in developing countries.

69 lation, and these numbers are even higher in developing countries.

70 sits for U.S. children and 218,000 deaths in developing countries.

71 forts are needed to fill the missing data in developing countries.

72 th potential positive implications for other developing countries.

73 Access to basic drugs is a major issue in developing countries.

74 rse outcomes and reduced vaccine efficacy in developing countries.

75 artisanal small-scale gold mining (ASGM) in developing countries.

76 s to be a leading cause of blindness in many developing countries.

77 ion annual deaths worldwide, most of them in developing countries.

78 protect people and livestock, especially in developing countries.

79 rus vaccine (IPV) is rarely used in tropical developing countries.

80 pares with many reports in the developed and developing countries.

81 ve been a factor in faster decreases in some developing countries.

82 utrient deficiencies are highly prevalent in developing countries.

83 cts an enormous financial and social cost on developing countries.

84 nues to suffer from anemic adoption rates in developing countries.

85 nd clinical laboratories, including those in developing countries.

86 icuous over the last decade, particularly in developing countries.

87 disease and death, especially in children in developing countries.

88 ns in China remains low, as it does in other developing countries.

89 here is little evidence on this question for developing countries.

90 well as POC diagnostics in resource-poor and developing countries.

91 e leading causes of blindness, especially in developing countries.

92 en of vision-impairing secondary membrane in developing countries.

93 tis has not been established in developed or developing countries.

94 marine biodiversity, especially in tropical developing countries.

95 unsafe, with 24.3 million (97%) of these in developing countries.

96 e intestinal disease and infant mortality in developing countries.

97 main sources of calories and protein in many developing countries.

98 Cancer is also a growing problem in developing countries.

99 ernative for cancer diagnosis, especially in developing countries.

100 settings, and virtually all deaths occur in developing countries.

101 ssibility and quality of cataract surgery in developing countries.

102 dy diarrhea each year, mostly in children in developing countries.

103 ially contribute to the food security in the developing countries.

104 -class drug still widely used, especially in developing countries.

105 an immunodeficiency virus/AIDS patients from developing countries.

106 temperature-YLL relationship, especially in developing countries.

107 and poses a threat to food-security in many developing countries.

108 l for fighting vitamin A deficiency (VAD) in developing countries.

109 been highly successful in both developed and developing countries.

110 he diminished RVV immunogenicity observed in developing countries.

111 ciency, which impedes their extensive use in developing countries.

112 f these tubers is vital for food security in developing countries.

113 ted to cause over 200,000 deaths annually in developing countries.

114 tion (EED) that severely affects children in developing countries.

115 o control vector-borne diseases continues in developing countries.

116 environmental consequences, particularly in developing countries.

117 long-term growth impairment in children from developing countries.

118 million refugees, mostly in refugee camps in developing countries.

119 Should income inequality be of concern in developing countries?

120 n below the age of five years, especially in developing countries(1,2).

121 es (20%, 17-22) compared with high-mortality developing countries (14%, 11-16; p=0.058).

122 In many developing countries a considerable proportion of CKD re

123 omas (HCCs) is dominated by its incidence in developing countries, accounting for >700,000 estimated

124 ance: Surgical care is widely unavailable in developing countries; advocates recommend that countries

125 mprehensive evaluation of surgical need in a developing country among the elderly.

126 with a ICER of $8.7/QALY, and affordable in developing countries and area where laboratory facilitie

127 ia coli (EPEC) primarily infects children in developing countries and causes diarrhea that can be dea

128 invasive amebiasis, which is endemic to many developing countries and characterized by dysentery and

129 review summarizes vaccination challenges in developing countries and discusses advantages that micro

130 whether outcomes are similar for donors from developing countries and donors with pre-existing condit

131 ia are intractable public health problems in developing countries and have profound short- and long-t

132 Respondents from developing countries and high-income countries rated the

133 ataract is the leading cause of blindness in developing countries and identification of the barriers

134 gricultural nitrous oxide (N2O) emissions in developing countries and in particular from tropical reg

135 e of acute viral hepatitis in people in many developing countries and is also endemic in many industr

136 cy (A(-)) remains a public health concern in developing countries and is associated with increased su

137 ake of these interventions have been slow in developing countries and many children suffering from di

138 g the changing impacts of the food system in developing countries and may inform future sustainabilit

139 e diagnosis of such infections is limited in developing countries and requires modern equipment in ad

140 hancement to alleviate these deficiencies in developing countries and to offer new functional foods i

141 mon bacteria causing diarrhea in children of developing countries and travelers to these countries, i

142 om studies of residents in or expatriates of developing countries and travelers to these regions wher

143 Rosenkranz Prize for Healthcare Research in Developing Countries and US National Institutes of Healt

144 iveness of influenza vaccination policies in developing countries and used it to consider annual vacc

145 on status in the United States compared with developing countries and, in turn, included a focus on i

146 fects one-third of children under 5 y old in developing countries, and 14% of childhood deaths are at

147 rtality is high in children aged <5 years in developing countries, and evaluations indicate waning pr

148 o therapeutic drugs continues to escalate in developing countries, and in many instances, it is due t

149 AS]) are highly prevalent in the tropics, in developing countries, and in the Indigenous populations

150 Stunting is common in young children in developing countries, and is associated with increased m

151 eful to those designing diagnostic tests for developing countries, and more generally, technologies f

152 xpanded Access to Cancer Care and Control in Developing Countries, and the Union for International Ca

153 to diarrheal illness among young children in developing countries, and there is currently no effectiv

154 However, in developing countries antibiotic therapy is commonly init

155 Only 27 developing countries are expected to achieve MDG 4.

156 Patients in developing countries are inadequately represented in pha

157 Developing countries are increasingly decentralizing for

158 Future studies in developed and developing countries are needed to further confirm our f

159 Mass treatment programs to cure HCV in developing countries are only feasible if the costs of t

160 aracteristics of child sexual abuse (CSA) in developing countries around the world are inconsistent a

161 ffered; India showed similarities with other developing countries (around 50% of DALYs attributable t

162 , it continues to be used in China and other developing countries as a global pollutant.

163 longitudinal data recently collected from 4 developing countries as part of the Young Lives study, w

164 blic demand for conservation within tropical developing countries as those countries reach upper-midd

165 ng virus causing epidemic acute hepatitis in developing countries as well as sporadic cases in indust

166 onment is a growing concern in developed and developing countries, as human exposure to metals is ass

167 uction structure and efficiency gains, while developing countries became the major destination of Chi

168 rculosis is a major cause of pericarditis in developing countries but accounts for less than 5% of ca

169 chistosomiasis is a prevalent disease in the developing countries, but in non-endemic areas diagnosis

170 common health-care-associated infections in developing countries, but they also represent a substant

171 rs may poorly estimate emissions in tropical developing countries by comparing calculator predictions

172 millions of self-employed business owners in developing countries by teaching basic financial and mar

173 Globally, growth faltering in developing countries caused a total economic cost of $17

174 suggest that early-life growth faltering in developing countries caused a total loss of 69.4 million

175 In rural India, as in many developing countries, childhood mortality remains high a

176 In contrast, for developing-country cities with emerging or nascent infra

177 European and Developing Countries Clinical Trial Partnership, Medicin

178 The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP)

179 Optimus Foundation, EuropeAID, and European Developing Countries Clinical Trials Partnership (EDCTP)

180 European & Developing Countries Clinical Trials Partnership (IP.200

181 ire Ontwikkelings Samenwerking, European and Developing Countries Clinical Trials Partnership, and th

182 rust, Medecins Sans Frontieres, European and Developing Countries Clinical Trials Partnership, Founda

183 European and Developing Countries Clinical Trials Partnership, Nation

184 European and Developing Countries Clinical Trials Partnership, South

185 European and Developing Countries Clinical Trials Partnership.

186 European Developing Countries Clinical Trials Partnership.

187 In a developing-country context, the International Monetary F

188 hat a large proportion of neonatal sepsis in developing countries could be effectively prevented usin

189 C-Kpn within a challenged health system of a developing country created the "perfect storm" for susta

190 However, thousands of people in developing countries die of rabies each year due to the

191 annot be universally accessed, especially in developing countries, due to the lack of effective treat

192 r-5 mortality rates are accelerating in many developing countries, especially in sub-Saharan Africa.

193 Children in developing countries experience multiple exposures that

194 ost 60% of individuals with dementia live in developing countries, few clinicopathological studies fo

195 approaches to demographic profiling, but in developing countries, fewer sources of big data exist.

196 organizations provide billions of dollars to developing countries for health.

197 and mortality due to infectious diarrhea in developing countries for which there is presently no eff

198 lso increased in children and adolescents in developing countries, from 8.1% (7.7-8.6) to 12.9% (12.3

199 Agriculture in developing countries has attracted increasing attention

200 Average inequality within developing countries has been slowly rising, though stay

201 cer, a major cause of monocular blindness in developing countries has consistently been listed as the

202 Funding for health in developing countries has increased substantially since 1

203 Trauma care capacity assessments in developing countries have generated evidence to support

204 n are indisputable, studies in developed and developing countries have reported conflicting findings

205 Although most infections occur in developing countries, HEV appears to be an emerging prob

206 lera and is the leading cause of diarrhea in developing countries, highlighting the need for the deve

207 ey adjunct therapy for childhood diarrhea in developing countries, however zinc's anti-diarrheal effe

208 regional CO2 emissions, particularly in many developing countries in Asia and Africa, are substantial

209 n supplying food and nutritional security in developing countries in Asia, Africa and the tropical Am

210 prove the participation of stakeholders from developing countries in the IPM adoption debate, and als

211 estimates of seasonal influenza mortality in developing countries in the tropics are lacking.

212 represented in global DAI than species-rich, developing countries in the tropics.

213 However, developing countries, in particular, Sub-Saharan African

214 In developing countries, inadequate screening options lead

215 9 y) is becoming increasingly common in many developing countries, including Bangladesh.

216 (PFOS) is an environmental toxicant used in developing countries, including China, as a stain repell

217 susceptibility information are long in many developing countries, including Panama, leading to delay

218 In many developing countries, increased use of fertilizers is a

219 Like a growing number of rapidly developing countries, India has begun to develop a syste

220 vices that have become readily accessible in developing countries--into a highly sensitive DNA detect

221 this study suggest that child development in developing countries is a dynamic process offering conti

222 limited access to virological monitoring in developing countries is a major weakness of the current

223 tainability of rural water infrastructure in developing countries is largely affected by the dynamic

224 e disease and colonization, but their use in developing countries is limited by restricted serotype c

225 However, vaccine administration in developing countries is limited by the difficulty in con

226 e of polluting and inefficient cookstoves in developing countries is necessary to achieve the potenti

227 e simplest, cheapest and only method used in developing countries like Ethiopia.

228 retinopathy are showing an alarming rise in developing countries like Zanzibar.

229 itis is a leading cause of blindness in many developing countries, likely the result of inadequate sc

230 of primary emissions from cookstoves used in developing countries may make important contributions to

231 In developing countries, mortality in children with very se

232 In developing countries, mortality results primarily from a

233 alsely perceived as a new phenomenon in some developing countries, most likely as a result of increas

234 izations (n = 38) that provided resources to developing countries (n = 146-183, depending on the year

235 n most areas of the world, especially in the developing countries of Asia and Africa.

236 legume crop that is primarily cultivated in developing countries of Asia.

237 anaesthesia) AND (neonatal OR newborn) AND (developing countries OR Africa)".

238 For developing countries, oversight is less intensive, and c

239 ance of rotavirus and oral polio vaccines in developing countries (PROVIDE) study.

240 specific beneficial effects in children from developing countries, reducing morbidity and mortality c

241 resuscitation protocol on sepsis outcomes in developing countries remains unknown.

242 As a group, developing-country respondents rated "IPM requires colle

243 warming below 2 degrees C while recognizing developing countries' right to eradicate extreme poverty

244 ect protection of 10-valent PCV (PCV10) in a developing country setting is unknown.

245 II showed good fit to predict mortality in a developing country setting.

246 tion of VDPV could be detected in a tropical developing country setting.

247 owever, this is done in several studies from developing country settings in which birthweight is eith

248 d from 2000 to 2010 pertinent to children in developing country settings, and identified 25 relevant

249 In sum, in infants in developing country settings, the ProSpecT EIA and PCR fo

250 ques are particularly challenging for use in developing country settings, where vitamin A deficiency

251 Appropriate use of antibiotics in developing countries should be encouraged.

252 post-neonatal cerebral palsy, especially in developing countries, should be possible through improve

253 As this disease is particularly prevalent in developing countries, simple and affordable CD4 cell cou

254 In many developing countries, simple biogas digesters are used t

255 In the 9 developing country sites, nasopharyngeal/oropharyngeal s

256 boratories at all tiers of health systems in developing countries, strengthening specimen referral ne

257 In rapidly developing countries, such as China, the highest levels

258 In developing countries, such as India, where combustion so

259 The few studies available from developing countries suggest prevalence of comparable ma

260 le macrosectors, especially when measured on developing countries, suggesting the emerging economies

261 unsafe abortions was significantly higher in developing countries than developed countries (49.5% vs

262 n rates were more than three times higher in developing countries than in industrialized countries (1

263 large patient populations especially in the developing countries that lack sufficient facilities and

264 tiveness of routine rotavirus vaccination in developing countries that were among the early adopters

265 In developing countries, the deployment of medical diagnost

266 As the prevalence of obesity increases in developing countries, the double burden of malnutrition

267 As a developing country, the importance of bioinformatics is

268 rge multicity studies have been conducted in developing countries to address the acute health effects

269 rograms operate in poor rural communities in developing countries to establish groups that save and t

270 ach could be adapted and replicated in other developing countries to inform rational health policy fo

271 h as riverbank filtration (RBF), are used in developing countries to treat irrigation water from rive

272 Increased efforts are needed, especially in developing countries, to ensure access to safe abortion.

273 The huge burden of malaria in developing countries urgently demands the development of

274 status and plans to make IPV affordable for developing-country use.

275 We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and

276 of orally administered rotavirus vaccines in developing countries, vaccine implementation in these se

277 urveillance studies of infant pertussis in a developing country, we identified a moderate burden of p

278 cause of blindness worldwide, especially in developing countries where access to cataract surgery re

279 able for elderly patients or for patients in developing countries where BL is endemic.

280 sorders have been conducted in (sub)tropical developing countries where exposure to multiple parasite

281 o be a major public health problem affecting developing countries where people eat mostly rice as a s

282 health containment efforts, particularly in developing countries where resources are few and EVD is

283 itude of yield gaps is particularly large in developing countries where smallholder farming dominates

284 py could have a large effect in hospitals in developing countries where the only respiratory support

285 olium (the pork tapeworm) is present in most developing countries, where it is a frequent cause of se

286 than half of new cases occur in economically developing countries, where more than two thirds of canc

287 xpensive, alternative diagnostic strategy in developing countries, where plaque reduction neutralizat

288 About 80% of affected patients live in developing countries, where pulmonary hypertension is fr

289 POC diagnostic assays play a crucial role in developing countries, where there are limited laboratory

290 ogens disproportionately afflict children in developing countries, where they cause substantial morbi

291 d health benefits result from diet shifts in developing countries whereas Western high-income and mid

292 of infectious diseases each year, mostly in developing countries, which could largely be prevented b

293 ncrease in overweight among individuals from developing countries who have been undernourished as chi

294 nvolving approximately 300,000 women from 24 developing countries who participated in Demographic and

295 ction of rotavirus vaccines, particularly in developing countries with diverse strains and lower effi

296 interrelate with the natural environment in developing countries with high economic disparities.

297 such as guiding safe iron supplementation in developing countries with high infection burden.

298 romising approaches for disease screening in developing countries with limited resources.

299 ee quarters of the world's suicides occur in developing countries, yet little is known about the driv

300 g cause of acute liver failure (ALF) in many developing countries, yet rarely identified in Western c